PMID- 10078988
OWN - NLM
STAT- MEDLINE
DCOM- 19990622
LR  - 20220423
IS  - 0014-2999 (Print)
IS  - 1879-0712 (Electronic)
IS  - 0014-2999 (Linking)
VI  - 367
IP  - 2-3
DP  - 1999 Feb 19
TI  - Chronic administration of adenosine A3 receptor agonist and cerebral ischemia: 
      neuronal and glial effects.
PG  - 157-63
AB  - We have previously shown that chronic administration of the selective A3 receptor 
      agonist N6-(3-iodobenzyl)-5'-N-methylcarboxoamidoadenosine (IB-MECA) leads to a 
      significant improvement of postocclusive cerebral blood flow, and protects 
      against neuronal damage and mortality induced by severe forebrain ischemia in 
      gerbils. Using immunocytochemical methods we now show that chronic with IB-MECA 
      results in a significant preservation of ischemia-sensitive microtubule 
      associated protein 2 (MAP-2), enhancement of the expression of glial fibrillary 
      acidic protein (GFAP), and a very intense depression of nitric oxide synthase in 
      the brain of postischemic gerbils. These changes demonstrate that the 
      cerebroprotective actions of chronically administered IB-MECA involve both 
      neurons and glial cells, and indicate the possibility of distinct mechanisms that 
      are affected in the course of chronic administration of the drug.
FAU - Von Lubitz, D K
AU  - Von Lubitz DK
AD  - Molecular Recognition Section, NIH/NIDDK, Bethesda, MD 20892, USA. 
      dvlubitz@umich.edu
FAU - Lin, R C
AU  - Lin RC
FAU - Boyd, M
AU  - Boyd M
FAU - Bischofberger, N
AU  - Bischofberger N
FAU - Jacobson, K A
AU  - Jacobson KA
LA  - eng
GR  - Z99 DA999999/ImNIH/Intramural NIH HHS/United States
GR  - Z01 DK031117/ImNIH/Intramural NIH HHS/United States
GR  - Z01 DK031117-20/ImNIH/Intramural NIH HHS/United States
GR  - Z99 OD999999/ImNIH/Intramural NIH HHS/United States
GR  - Z99 DK999999/ImNIH/Intramural NIH HHS/United States
PT  - Journal Article
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Coloring Agents)
RN  - 0 (Glial Fibrillary Acidic Protein)
RN  - 0 (Microtubule-Associated Proteins)
RN  - 0 (Purinergic P1 Receptor Agonists)
RN  - 0 (Receptors, Purinergic P1)
RN  - 152918-18-8 (N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase)
RN  - K72T3FS567 (Adenosine)
SB  - IM
MH  - Adenosine/administration & dosage/*analogs & derivatives/pharmacology
MH  - Animals
MH  - Brain Chemistry/*drug effects
MH  - Carotid Arteries
MH  - Coloring Agents
MH  - Female
MH  - Gerbillinae
MH  - Glial Fibrillary Acidic Protein/drug effects/*metabolism
MH  - Immunohistochemistry
MH  - Ischemia/metabolism/*pathology
MH  - Microtubule-Associated Proteins/drug effects/*metabolism
MH  - Nitric Oxide Synthase/drug effects/*metabolism
MH  - Purinergic P1 Receptor Agonists
MH  - Receptors, Purinergic P1/administration & dosage
MH  - Time Factors
PMC - PMC3469161
MID - NIHMS410021
EDAT- 1999/03/17 00:00
MHDA- 1999/03/17 00:01
PMCR- 2012/10/11
CRDT- 1999/03/17 00:00
PHST- 1999/03/17 00:00 [pubmed]
PHST- 1999/03/17 00:01 [medline]
PHST- 1999/03/17 00:00 [entrez]
PHST- 2012/10/11 00:00 [pmc-release]
AID - S0014-2999(98)00977-7 [pii]
AID - 10.1016/s0014-2999(98)00977-7 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 1999 Feb 19;367(2-3):157-63. doi: 10.1016/s0014-2999(98)00977-7.